San Diego Business Journal

Cadence Pharmaceuticals said March 12 it was ending plans to develop its topical anti-infective gel Omigard after the drug failed to meet its goals in a late-stage study...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $99